Advaxis Inc. (ADXS) had a good day on the market for Thursday January 31 as shares jumped 11.44% to close at $0.38. About 603,323 shares traded hands on 1,241 trades for the day, compared with an average daily volume of n/a shares out of a total float of 69.7 million. After opening the trading day at $0.34, shares of Advaxis Inc. stayed within a range of $0.38 to $0.34.
With today’s gains, Advaxis Inc. now has a market cap of $26.42 million. Shares of Advaxis Inc. have been trading within a range of $3.08 and $0.18 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Advaxis Inc is a clinical stage biotechnology company operating in the United States. It focuses on discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology which utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company’s immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) – associated cancers and ADXS-PSA which targets Prostate Specific Antigen (PSA) associated with prostate cancer.
Advaxis Inc. is based out of Princeton, NJ and has some 108 employees. Its CEO is Kenneth A. Berlin.